T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
The surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions. However, the administration of exogenous biologics could potentially trigger unwanted immune responses such as generation of anti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2324836 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576536427888640 |
|---|---|
| author | Ruoxuan Sun Mark G. Qian Xiaobin Zhang |
| author_facet | Ruoxuan Sun Mark G. Qian Xiaobin Zhang |
| author_sort | Ruoxuan Sun |
| collection | DOAJ |
| description | The surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions. However, the administration of exogenous biologics could potentially trigger unwanted immune responses such as generation of anti-drug antibodies (ADAs). Real-world experiences have illuminated the clear correlation between the ADA occurrence and unsatisfactory therapeutic outcomes as well as immune-related adverse events. By retrospectively examining research involving immunogenicity analysis, we noticed the growing emphasis on elucidating the immunogenic epitope profiles of antibody-based therapeutics aiming for mechanistic understanding the immunogenicity generation and, ideally, mitigating the risks. As such, we have comprehensively summarized here the progress in both experimental and computational methodologies for the characterization of T and B cell epitopes of therapeutics. Furthermore, the successful practice of epitope-driven deimmunization of biotherapeutics is exceptionally highlighted in this article. |
| format | Article |
| id | doaj-art-35791c01bb7b437085106c688356d180 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-35791c01bb7b437085106c688356d1802025-01-31T04:19:38ZengTaylor & Francis GroupmAbs1942-08621942-08702024-12-0116110.1080/19420862.2024.2324836T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeuticsRuoxuan Sun0Mark G. Qian1Xiaobin Zhang2Global Drug Metabolism, Pharmacokinetics & Modeling, Preclinical & Translational Sciences, Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USAGlobal Drug Metabolism, Pharmacokinetics & Modeling, Preclinical & Translational Sciences, Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USAGlobal Drug Metabolism, Pharmacokinetics & Modeling, Preclinical & Translational Sciences, Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USAThe surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions. However, the administration of exogenous biologics could potentially trigger unwanted immune responses such as generation of anti-drug antibodies (ADAs). Real-world experiences have illuminated the clear correlation between the ADA occurrence and unsatisfactory therapeutic outcomes as well as immune-related adverse events. By retrospectively examining research involving immunogenicity analysis, we noticed the growing emphasis on elucidating the immunogenic epitope profiles of antibody-based therapeutics aiming for mechanistic understanding the immunogenicity generation and, ideally, mitigating the risks. As such, we have comprehensively summarized here the progress in both experimental and computational methodologies for the characterization of T and B cell epitopes of therapeutics. Furthermore, the successful practice of epitope-driven deimmunization of biotherapeutics is exceptionally highlighted in this article.https://www.tandfonline.com/doi/10.1080/19420862.2024.2324836Anti-drug antibodyantibodyB cell epitopedeimmunizationepitopeimmunogenicity |
| spellingShingle | Ruoxuan Sun Mark G. Qian Xiaobin Zhang T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics mAbs Anti-drug antibody antibody B cell epitope deimmunization epitope immunogenicity |
| title | T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics |
| title_full | T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics |
| title_fullStr | T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics |
| title_full_unstemmed | T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics |
| title_short | T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics |
| title_sort | t and b cell epitope analysis for the immunogenicity evaluation and mitigation of antibody based therapeutics |
| topic | Anti-drug antibody antibody B cell epitope deimmunization epitope immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2324836 |
| work_keys_str_mv | AT ruoxuansun tandbcellepitopeanalysisfortheimmunogenicityevaluationandmitigationofantibodybasedtherapeutics AT markgqian tandbcellepitopeanalysisfortheimmunogenicityevaluationandmitigationofantibodybasedtherapeutics AT xiaobinzhang tandbcellepitopeanalysisfortheimmunogenicityevaluationandmitigationofantibodybasedtherapeutics |